Modified FOLFIRINOX for Unresectable Locally Advanced/Metastatic Pancreatic Cancer. A Real-World Comparison of an Attenuated with a Full Dose in a Single Center Experience

Purpose of Study: Metastatic pancreatic adenocarcinoma has a very poor prognosis. Although irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX) significantly increases survival in advanced pancreatic cancer, compared to employing only gemcitabine (GEM), toxicities have tempered enthusiasm for its use.